[Federal Register Volume 66, Number 226 (Friday, November 23, 2001)]
[Notices]
[Pages 58745-58746]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-29225]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Arthritis Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on December 7, 2001, from 8 
a.m. to 5 p.m.
    Location: CDER Advisory Committee conference room 1066, 5630 
Fishers Lane, Rockville, MD.
    Contact: Kathleen Reedy or LaNise Giles, Center for Drug Evaluation 
and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, 
(for express delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD 
20857, 301-827-7001, FAX: 301-827-6776 or e-mail: [email protected], 
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), code 12532. Please call the 
Information Line for up-to-date information on this meeting.
    Agenda: The meeting will be open to the public from 8 a.m. to 9 
a.m., unless public participation does not last that long, from 9 a.m. 
to 5 p.m., the meeting will be closed to permit discussion and review 
of trade secret and/or confidential information.
    Procedure: On December 7, 2001, from 8 a.m. to 9 a.m., the meeting 
will open to the public. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Written submissions may be made to the contact person by 
November 17, 2001. Oral presentations from the public will be scheduled 
between approximately 8 a.m. and 9 a.m. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before November 17, 
2001, and submit a brief statement of the general nature of the 
evidence or arguments they wish to present, the names and addresses of 
proposed participants, and an indication of the approximate time 
requested to make their presentation.
    FDA regrets that it was unable to publish this notice 15 days prior 
to the December 7, 2001, Arthritis Advisory Committee meeting. Because 
the agency believes there is some urgency to bring this issue to public 
discussion and qualified members of the Arthritis Advisory Committee 
were available at this time, the Commissioner of Food and Drugs 
concluded that it was in the public interest to hold this meeting even 
if there was not sufficient time for the customary 15-day public 
notice.
    Closed Committee Deliberations: On December 7, 2001, from 9 a.m. to 
5 p.m., the meeting will be closed to permit

[[Page 58746]]

discussion and review of trade secret and/or confidential information 
(5 U.S.C. 552b(c)(4)).
    Notice of this meeting is given under the Federal Advisory 
Committee Act 5 U.S.C. app. 2).

    Dated: November 15, 2001.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 01-29225 Filed 11-21-01; 8:45 am]
BILLING CODE 4160-01-S